3.29
0.23 (7.52%)
| Previous Close | 3.06 |
| Open | 3.10 |
| Volume | 1,137,936 |
| Avg. Volume (3M) | 596,505 |
| Market Cap | 348,832,128 |
| Price / Sales | 6.43 |
| Price / Book | 1.23 |
| 52 Weeks Range | |
| Earnings Date | 13 Jan 2025 |
| Profit Margin | -110.92% |
| Operating Margin (TTM) | -118.33% |
| Diluted EPS (TTM) | -0.400 |
| Quarterly Revenue Growth (YOY) | -8.40% |
| Total Debt/Equity (MRQ) | 9.44% |
| Current Ratio (MRQ) | 12.23 |
| Operating Cash Flow (TTM) | -31.46 M |
| Levered Free Cash Flow (TTM) | -13.08 M |
| Return on Assets (TTM) | -13.12% |
| Return on Equity (TTM) | -19.63% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bearish | Bearish |
| Medical Devices (Global) | Bearish | Bearish | |
| Stock | MaxCyte, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | 1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | -0.90 |
|
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 1.45% |
| % Held by Institutions | 75.79% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| River Global Investors Llp | 31 Dec 2024 | 3,253,192 |
| Mudita Advisors Llp | 31 Dec 2024 | 3,223,407 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| AL-WAKEEL YASIR B. | 2.11 | - | 29,210 | 61,633 |
| BALTHROP PATRICK J | 2.11 | - | 29,210 | 61,633 |
| BROOKE WILLIAM W | 2.11 | - | 29,210 | 61,633 |
| COLLINS CYNTHIA | 2.11 | - | 29,210 | 61,633 |
| DOUGLAS RICHARD | 2.11 | - | 29,210 | 61,633 |
| ERCK STANLEY C | 2.11 | - | 29,210 | 61,633 |
| HEMRAJANI REKHA | 2.11 | - | 29,210 | 61,633 |
| JOHNSTON JOHN JOSEPH | 2.11 | - | 29,210 | 61,633 |
| Aggregate Net Quantity | 233,680 | |||
| Aggregate Net Value ($) | 493,065 | |||
| Aggregate Avg. Buy ($) | 2.11 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| AL-WAKEEL YASIR B. | Director | 18 Jun 2025 | Acquired (+) | 29,210 | 2.11 | 61,633 |
| BALTHROP PATRICK J | Director | 18 Jun 2025 | Acquired (+) | 29,210 | 2.11 | 61,633 |
| BROOKE WILLIAM W | Director | 18 Jun 2025 | Acquired (+) | 29,210 | 2.11 | 61,633 |
| COLLINS CYNTHIA | Director | 18 Jun 2025 | Acquired (+) | 29,210 | 2.11 | 61,633 |
| DOUGLAS RICHARD | Director | 18 Jun 2025 | Acquired (+) | 29,210 | 2.11 | 61,633 |
| ERCK STANLEY C | Director | 18 Jun 2025 | Acquired (+) | 29,210 | 2.11 | 61,633 |
| HEMRAJANI REKHA | Director | 18 Jun 2025 | Acquired (+) | 29,210 | 2.11 | 61,633 |
| JOHNSTON JOHN JOSEPH | Director | 18 Jun 2025 | Acquired (+) | 29,210 | 2.11 | 61,633 |
| Date | Type | Details |
|---|---|---|
| 11 Jun 2025 | Announcement | MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies |
| 07 May 2025 | Announcement | MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance |
| 07 May 2025 | Announcement | MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance |
| 10 Apr 2025 | Announcement | MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |